Antiarrhythmic Effects of Aspirin during Nonthrombotic Coronary Occlusion

CHRISTOS B. MOSCHOS, M.D., BUNYAD HAIDER, M.D.,
CATALINO DE LA CRUZ, JR., M.D., MICHAEL M. LYONS, M.D., AND TIMOTHY J. REGAN, M.D.

SUMMARY To study the action of aspirin upon the myocardium per se, independent of thrombosis, coronary occlusion with a balloon catheter was induced in 53 anesthetized dogs divided into two groups. One group (N = 20) was treated daily with aspirin (600 mg/dog) for seven days and another (N = 33) was untreated. Left ventricular hemodynamics and precordial ECG mapping were used to assess the influence of myocardial ischemia over a four hour period. There were no significant differences in left ventricular function or extent of injury as judged by ECG mapping between the two groups. However, there was a significant decrease in the incidence of ventricular fibrillation in the treated dogs (5% vs 39%). Serial plasma samples for free fatty acid determination showed a significant rise in the untreated group. Aspirin blocked the FFA increment in the treated animals. Tissue samples from the ischemic area of left ventricle exhibited a significant reduction of the sodium and water increments, as well as a lesser potassium loss in the treated animals compared to the controls and may have been the basis for the lower incidence of arrhythmias. Since infusion of 4Cr labelled platelets showed no myocardial accumulation of platelets in either group, microthrombi did not appear to contribute to the observed differences.

ANTI-INFLAMMATORY AGENTS interfere with platelet aggregation.1, 2 A number of investigations have examined these effects of anti-inflammatory agents upon platelet function but there has been limited evaluation of the responses of other cells and tissues. In a recent experimental study, we evaluated the effects of aspirin pretreatment upon survival following coronary thrombosis induced by means of a catheter electrode.3 Despite the inability of aspirin to inhibit the formation of a platelet thrombus in the epicardial coronary vessels of this model, survival of the animals was significantly increased.

In subsequent studies, we postulated that the reduced incidence of ventricular fibrillation in the aspirin treated animals was probably due to a decrease in microcirculatory thrombosis which was observed in untreated animals with epicardial thrombotic obstruction.4 Alternatively, an action of aspirin upon the myocardium itself independent of thrombosis may influence the ischemic process and the incidence of arrhythmias. To test this potential mechanism we produced a nonthrombotic coronary occlusion with a balloon catheter in intact anesthetized dogs.

Methods

A total of 57 apparently healthy male mongrel dogs weighing from 21–26 kg were used. Twenty-one of the animals were placed on aspirin by mouth in the amount of 600 mg/day for seven consecutive days prior to the day of the experiment. The remaining dogs were used as controls. After an 18 hour fast, all animals on the day of the experiment were anesthetized with morphine sulfate (3 mg/kg of body weight given intramuscularly) and sodium phenobarbital (20 mg/kg of body weight given intravenously) and subsequently were placed on a respiratory pump to maintain adequate ventilation. Frequent pH determinations were performed to confirm maintenance within the physiologic range. While blood gases were not assessed, arterial samples for substrate taken during the course of the study appeared to be well oxygenated. We have previously observed that pO2 is generally well maintained during experiments of this type.5 The left jugular vein and left and right carotid arteries were exposed through small skin incisions. Number 8F catheters were passed into the left ventricle via the right carotid artery and at the root of the aorta via the femoral artery. Left ventricular and aortic pressures were recorded by means of Statham strain gauge transducers using an Electronics for Medicine DR-8 amplifier recorder. Cardiac output was determined by the thermodilution technique6 with the thermodilution catheter placed in the main pulmonary artery via a jugular vein. All animals were under continuous electrocardiographic monitoring.

Myocardial ischemia was induced by means of a double lumen balloon tipped catheter inserted through the left carotid artery and positioned under fluoroscopic control in the left anterior descending coronary artery (LAD) approximately 2.5 cm from its origin. After determining control hemodynamic parameters prior to the induction of ischemia, the balloon was inflated with approximately 1 ml of air and peripheral coronary pressure was monitored using a Statham strain gauge. Complete coronary occlusion was evidenced by a reduction of mean peripheral coronary pressure to approximately 30 mm Hg and the appearance of an injury potential on standard lead I. No antiarrhythmic drugs were used and animals that fibrillated within the initial 15 minute high risk period were excluded from the study, including three animals from the untreated group and one from the treated group. The experiment was designed for a four hour period during which the hemodynamic parameters and electrocardiograms were continuously monitored and intermittently recorded along with cardiac output. Estimation of size of the ischemic area was made during the four hour period from 20 precordial ECG leads7 determining the number with ST elevation (N-ST) and the sum of the ST elevation (ΣST), using an electrical calibration of 0.1 mV. Serial arterial blood samples were taken from both groups for plasma free fatty acid determination.8

At the conclusion of the studies, the thorax was incised and the heart was rapidly arrested with iced Ringer's solu-
TABLE 1. Study Groups

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Aspirin-treated*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of animals</td>
<td>33</td>
<td>20</td>
</tr>
<tr>
<td>Hemodynamics</td>
<td>8</td>
<td>10</td>
</tr>
<tr>
<td>ECG mapping</td>
<td>18</td>
<td>10</td>
</tr>
<tr>
<td>Platelet-14Cr studies</td>
<td>7</td>
<td>4</td>
</tr>
<tr>
<td>Tissue electrolytes</td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td>Plasma FFA</td>
<td>8</td>
<td>7</td>
</tr>
</tbody>
</table>

*Treatment was 600 mg/day for seven days.

Results

Table 1 summarizes the groups studied as well as the number of animals and the procedures employed to assess the effects of aspirin pretreatment upon a four hour non-thrombotic coronary occlusion. As shown in table 2 the only significant hemodynamic change occurred in the untreated group with a decrease in stroke volume significant at the P < 0.01 level. Precordial ECG mapping indicated that in the untreated animals, the ΣST rose slightly from 4.41 ± 0.74 mV at 15 minutes to 4.50 ± 0.73 mV over a four hour period. In the aspirin treated animals ΣST fell from 6.25 ± 1.60 mV to 4.23 ± 0.89 but this was not significantly different from the untreated group. The extent of ischemia as judged by the N-ST remained unchanged in the untreated animals, from 14 ± 1.11 to 14.53 ± 1.25 sites. The tendency in the treated group for the N-ST to decrease, from 12.4 ± 1.52 at 15 minutes of ischemia to 9.38 ± 1.34 sites at four hours, was also not significant when compared with the untreated animals.

Analysis of electrolyte composition in the ischemic tissue of untreated animals showed a significant increase of sodium and water associated with a decrease of K* concentration in all myocardial layers compared to the nonischemic area (table 3). In the aspirin treated group the degree of intracellular sodium increase and potassium decrease in the ischemic area was less than for the nontreated group. Thus comparing the ischemic areas of the treated and nontreated groups, this difference was significant for sodium in the outer layers and potassium in the inner layers and the gain of water was significantly less in all layers. It should be noted that even the nonischemic tissue in the aspirin treated animals contained significantly less water than the nonischemic tissue of the untreated animals (P < 0.01). Since the only variable between the two groups was aspirin pretreatment, such differences may be associated with the effects of aspirin, the nature of which are not clear.

Free fatty acid levels in arterial plasma of untreated animals rose during ischemia from a control of 210 ± 38 µEq/L to 696 ± 246 µEq/L by four hours (P < 0.05). In the

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Aspirin-treated*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of animals</td>
<td>33</td>
<td>20</td>
</tr>
<tr>
<td>Hemodynamics</td>
<td>8</td>
<td>10</td>
</tr>
<tr>
<td>ECG mapping</td>
<td>18</td>
<td>10</td>
</tr>
<tr>
<td>Platelet-14Cr studies</td>
<td>7</td>
<td>4</td>
</tr>
<tr>
<td>Tissue electrolytes</td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td>Plasma FFA</td>
<td>8</td>
<td>7</td>
</tr>
</tbody>
</table>

TABLE 2. Hemodynamic Parameters

<table>
<thead>
<tr>
<th></th>
<th>Untreated</th>
<th>Treated</th>
<th>Untreated</th>
<th>Treated</th>
<th>Untreated</th>
<th>Treated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart rate (beats/min)</td>
<td>147 ± 9</td>
<td>131 ± 7.9</td>
<td>142 ± 8.1</td>
<td>126 ± 6.7</td>
<td>135 ± 9.3</td>
<td>120 ± 8.65</td>
</tr>
<tr>
<td>Aortic pressure (mm Hg)</td>
<td>130 ± 8.2</td>
<td>119 ± 7.2</td>
<td>127 ± 10.1</td>
<td>120 ± 8.4</td>
<td>133 ± 3.6</td>
<td>117 ± 10.3</td>
</tr>
<tr>
<td>LVEDP pressure (mm Hg)</td>
<td>12 ± 2.0</td>
<td>10 ± 1.2</td>
<td>12 ± 1.2</td>
<td>11 ± 1.2</td>
<td>16 ± 3.14</td>
<td>14 ± 1.3</td>
</tr>
<tr>
<td>SV (ml)</td>
<td>27.1 ± 2.5</td>
<td>17.8 ± 2.5</td>
<td>24.36 ± 1.23</td>
<td>16.22 ± 1.74</td>
<td>16.0 ± 1.94</td>
<td>14.83 ± 1.60</td>
</tr>
</tbody>
</table>

*P < 0.01 compared to their own control levels.

Abbreviations: SV = stroke volume; LVEDP = left ventricular end-diastolic pressure.
aspirin treated group this response was aborted. Control levels at 232 ± 46 μEq/L did not differ significantly from the four hour levels of 287 ± 42 μEq/L.

Table 4 indicates the average radioactivity distribution of labelled platelets in the myocardium after four hours of coronary occlusion in the treated and nontreated animals. There were no differences in platelet radioactivity distribution and presumably microcirculatory thrombosis between treated and untreated animals. This was in agreement with microscopic evaluation. No platelet aggregates in numerous random sections of myocardium were found in either group. It should also be noted that there was no evidence of thrombus formation by gross inspection distal or proximal to the site of the occlusion in this series of experiments.

Fourteen animals died of ventricular fibrillation between 20 minutes and three hours following balloon occlusion. The differences between treated and nontreated groups were significant by the χ² test (0.025 < P < 0.05). Thirteen of 33 (39%) untreated animals died whereas only one of 20 in the treated group (5%) died during the four hour observation period.

**Discussion**

The results of this study indicate that aspirin pretreatment can reduce the incidence of ventricular fibrillation associated with myocardial ischemia induced by mechanical obstruction of a coronary artery. We have observed previously that thrombotic obstruction is associated with microthrombi in the small vessels of the myocardium, detectable by the labelled platelet technique. The latter process was prevented by aspirin pretreatment. During balloon occlusion in the untreated animals of this study, no microthrombi were found, as was true of those receiving aspirin. The failure to observe significant platelet accumulation microscopically or by radioactivity counts in either the untreated or treated animals indicated that microcirculatory thrombosis was not the issue in this model. In addition, there was no evidence in any of the animals of thrombus formation distal or proximal to the site of the balloon occlusion which might have served as an embolic source. The therapeutic effect of aspirin upon mortality when microcirculatory thrombosis is secondary to thrombus in an epicardial vessel, suggests a composite action upon myocardium as well as platelets.

The differences in hemodynamic parameters observed between treated and nontreated animals at control time, although consistent, were with one exception not statistically significant. It is plausible that an antiadrenergic action of aspirin (see below) would affect pressure and heart rate as well as stroke volume in the manner observed in this study. We have, however, in a prior study observed no difference in the incidence of ventricular fibrillation when animals with

---

**Table 4. Radioactivity Distribution (Platelet-51Cr) after Four Hour Coronary Occlusion**

<table>
<thead>
<tr>
<th>Group</th>
<th>N</th>
<th>(ischemic/nonischemic) Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nontreated</td>
<td>7</td>
<td>1.30</td>
</tr>
<tr>
<td>Aspirin treated</td>
<td>4</td>
<td>1.44*</td>
</tr>
</tbody>
</table>

*P = NS.
stable preischemic heart rates of 80 to 100 per minute were compared to those with significantly higher levels. This is not the case when heart rate is acutely increased during ischemia.

Despite the failure to find a significant difference in the hemodynamic response or the area of ischemia as judged by the multiple precordial ECG leads, there was a significant difference in the electrolyte and water composition of the ischemic area. The aspirin treated group exhibited less loss of potassium and gain of sodium and water compared to untreated animals. This may have been the basis for the reduced incidence of fibrillation, as has been suggested during the use of classical antiarrhythmic agents.8

Whether aspirin has a direct or indirect effect on the myocardium to alter electrolyte and arrhythmia incidence is not known. Salicylates have been shown to inhibit catecholamine-induced lipolysis in vitro.12,13 Since the rise of plasma free fatty acids, postulated by others to increase arrhythmia incidence during untreated myocardial ischemia,14 was prevented in the aspirin treated group, the action of this agent may be related to this alteration of lipid transport. Further, since aspirin has been observed to reduce catecholamine-induced vasoconstriction,15 an inhibitory action on catecholamines in the myocardium may be a basis for an antiarrhythmic response during acute ischemia.16 In therapeutic dose aspirin has been found to decrease cAMP in lymphocytes as well as inhibit the rise of the nucleotide in these cells in response to isoproterenol and prostaglandin.17 Such an action of aspirin in the myocardium may be a basis for antiarrhythmic activity since enhanced cAMP formation in the ischemic myocardium has been postulated to be a major factor in the genesis of arrhythmias.18

Acetyl salicylic acid may also act through inhibition of prostaglandin or its endoperoxide precursors.19 However, it should be noted that the acute administration of indomethacin to inhibit prostaglandin synthesis during myocardial ischemia was associated with evidence of enhanced injury, suggesting that prostaglandin, instead of promoting injury during ischemia, may be protective.20

We have previously reported that the blood levels of aspirin achieved by this dose regimen was in therapeutic range for man.3 Whether a dosage and duration of therapy are critical to the observed response require further delineation.

Acknowledgments

The authors wish to thank Mrs. Marilyn Pittman for secretarial services.

References

Antiarrhythmic effects of aspirin during nonthrombotic coronary occlusion.
C B Moschos, B Haider, C De La Cruz, Jr, M M Lyons and T J Regan

_Circulation_. 1978;57:681-684
doi: 10.1161/01.CIR.57.4.681

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1978 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/57/4/681

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org//subscriptions/